Impact of the COVID-19 pandemic and its measures on one-year and three-year cancer survival using Swiss cantonal cancer registry data

Lung, Respiratory and Thoracic Cancer

Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)

Eur J Cancer

Houda I, Naves D, Ulas EB, Lissenberg-Witte BI, Barlo NP, Kastelijn EA, Bouhaddou H, Shaikh R, Dickhoff C, Radonic T, Schneiders FL, Senan S, Damhuis RAM, Bahce I

doi: 10.1016/j.ejca.2025.116042

Further Publications

Impact of COVID-19 and vaccination on long-term survival in patients with solid malignancies: A nationwide cohort study

Eur J Cancer

Dimitrov G, Argirova R, Valkov T

doi: 10.1016/j.ejca.2026.116708

Breast Cancer

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry

Int J Cancer

Marschner P, Ringwald K, Thill M, Zahn MO, Welt A, Nusch A, Kaltenecker G, Rodemer Y, Hagen V, Schock C, Kruggel L, Kaiser-Osterhues A, Klein D, Haug N, Stickeler E, Harbeck N, Wöckel A, Marschner N, Decker T, OPAL Registry Group

doi: 10.1002/ijc.70433

Genitourinary Cancer

Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany

Prostate Cancer Prostatic Dis

Sondermann M, Stehr A, Hirtsiefer C, Menzel V, Buttmann-Schweiger N, Flemming PW, Kraywinkel K, Thomas C, Boehm K

doi: 10.1038/s41391-026-01092-w

Lung, Respiratory and Thoracic Cancer

Clinical characteristics and survival of small cell lung cancer with limited or extensive synchronous metastatic spread - A German population-based cancer-registry based cohort study

Lung Cancer

Schliemann A, Waldmann A, Katalinic A, Kim-Wanner SZ, Pritzkuleit R, Twardella D, Bertram S

doi: 10.1016/j.lungcan.2026.109448

Gastrointestinal Cancer

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Int J Cancer

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group

doi: 10.1002/ijc.70280

Breast Cancer

Aprepitant use during chemotherapy and association with survival in women with early breast cancer

J Natl Cancer Inst

Botteri E, Hjorth S, Conforti F, Bagnardi V, Andreassen BK, Støer NC, Bhargava S, Ursin G, Gandini S, Sloan EK, Chang A

doi: 10.1093/jnci/djaf178

Genitourinary Cancer

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Ann Oncol

Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, Shevrin DH, Cooney MM, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney CJ

doi: 10.1016/j.annonc.2025.08.004

ASH 2025

Lymphoma

Related content